Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).


Abulkhair O., Uslu R., Sezgin C., Bueyuekberber S., Darwish T., Isikdogan A., ...More

CANCER RESEARCH, vol.72, 2012 (Journal Indexed in SCI) identifier